FAST MONEY FEATURES
FAST MONEY POLLGet in the post game. Respond to our "Question of the Day" right now.
FULL SHOWSMissed an episode of Fast Money? Watch the lastest show here.
TRADE SCHOOLGrab a pencil because school is in session and the Fast Money traders are teaching class.
FAST MONEY PODCASTSDownload Fast Money onto your MP3 Player.
FAST MONEY WIDGETGrab this all-in-one application and get recaps of the show sent right to your desktop or blog.
SHOP FOR FAST MONEY MERCHANDISEGet your game on with Fast Money gear.
FAST MONEY PHOTOS!Check out our scrapbook. These "pix" are guaranteed winners.
NEWSLETTERSign up and receive a recap email every Friday after the show!
FAST MONEY MOBILE ALERTSGet advanced information about the next Fast Money.
Text Size 
 |
On Monday President Obama named Kansas Governor Kathleen Sebelius to lead his ambitious health reform effort, kicking off a week focused on revamping an inefficient healthcare system whose cost he fears is hurting the U.S. economy.
As you might remember some of Obama’s reforms include providing insurance to those who don’t currently have coverage, making it easier for people to get generic drugs, and streamlining medical records.
As a result investors pummeled a wide range of companies in the healthcare space – everything from Merck [MRK
Loading...
()
] to UnitedHealthcare [UNH
Loading...
()
] -- reasoning that the new rules would strangle profits.
But why is that?
CNBC’s Mike Huckman explains that “the President is proposing that there be greater rebates to Medicaid on the popular drugs that Medicaid purchases. That brings down margins for Big Pharama."
"Also," he says, "the President is trying to create a road map for generic versions of biotech drugs. That’s what’s pressuring Biotech."
What’s the trade?
Keep an eye on Genenech [DNA
Loading...
()
], counsels Huckman. If you're willing to take a risk on data, the results on Avastin are due soon. If they're strong the stock could go to $100 and maybe even put it out of Roche’s reach in their acquisition attempt.
And also keep an eye on Dendreon [DNDN
Loading...
()
], for their results on prostate cancer, he counsels.
- Your First Move For Wednesday November 25th
- Web Extra: Seymour's M&A Play
- Pops & Drops: American Eagle, Green Mountain Coffee...
- Giving Thanks: Najarian
- Take Your Position: Cyber Monday
- Rick's Turkey: Fed Transparency
- Under The Radar Trades
- Our Best Black Friday Trades
- GDP Drags Stocks Lower
- Halftime Report: Is Oil Heading To $96?
______________________________________________________
Got something to to say? Send us an e-mail at and your comment might be posted on the Rapid Recap. If you'd prefer to make a comment but not have it published on our website send those e-mails to .
Trader disclosure: On Mar. 2nd, 2009, the following stocks and commodities mentioned or intended to be mentioned on CNBC’s Fast Money were owned by the Fast Money traders; Seymour Owns (AAPL), (EEM), (BAC), (FXI); Seymour's Firm Owns (FCX); Terranova Owns (DIS), (FXC), (XBI), (BRCM), (WYNN), (INTC), (DELL), (JOYG); Terranova Owns (AMGN) & (AMGN) Puts; Terranova Owns (IBM) Call Spread; Terranova Owns (COP) Calls; Terranova Owns MACI Oil Futures; Macke Owns (MS), (GS), (SDS), (TM), (AAPL), (WOS); Karabell Owns (AAPL), (FCX), (GOOG), (GLD), (GE), (JPM)
CNBC.com with wires
Data is a real-time snapshot *Data is delayed at least 15 minutes